OKYO Pharma Ltd
OKYO · Biological Products, (No Diagnostic Substances) · EDGAR filings ↗
Grade
D43Micro-cap clinical-stage eye-disease biotech with an explicit going-concern doubt and near-exhausted cash.
Strengths
- Positive Phase 2 dry-eye signal (statistically significant pain reduction) supports the urcosimod NCP program
- Large one-time tax credit narrowed the FY25 loss
Risks
- Going-concern opinion; only ~$1.6M cash and a $5.6M working-capital deficit (cash bottom decile, 10th pct)
- No revenue for years if ever; must raise substantial capital on potentially dilutive terms
- Early-stage pipeline with high clinical failure risk
Notable findings
- Going concernOur independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing
Key metrics
Cash & investments
$5M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-08 | CERRONE GABRIELE M | Grant | 300K | $1.72 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06637527 ↗ | The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain Neuropathic Pain | PHASE2 | Terminated | 2025-04-30 |
| NCT05759208 ↗ | The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease Dry Eye Disease | PHASE2 | Completed | 2023-12-15 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-07-18 | 2025-03-31 | 0001641172-25-020240 ↗ |
| 20-F | 2024-08-13 | 2024-03-31 | 0001493152-24-031640 ↗ |
| 20-F | 2023-08-15 | 2023-03-31 | 0001493152-23-028739 ↗ |
| 20-F | 2022-08-15 | 2022-03-31 | 0001493152-22-022836 ↗ |